Part, Chapter, Paragraph
1 II, 5. 5. 1| includes prevalence in %, as a cumulative number of all registered
2 II, 5. 5. 3| limited European data on the cumulative incidence (Beghi and Cornaggia,
3 II, 5. 5. 3| and Cornaggia, 2002). The cumulative probability of illness by
4 II, 5. 5. 3| controls (p<0.0001). The cumulative probability of accident
5 II, 5. 5. 3| epilepsy reported a 69% cumulative 5-year remission rate at
6 II, 5. 6. 3| explained partly by a cumulative effect of chronic musculoskeletal
7 II, 5. 8. 3| Northern Sweden, a 10-year cumulative incidence rate according
8 II, 5. 8. 3| was considered: the 7-year cumulative incidence of COPD was 11.
9 II, 5. 8. 3| Johannessen et al (2005) reported cumulative incidence rates of GOLD-defined
10 II, 5. 8. 3| Countries Study, the 30-year cumulative incidences of chronic bronchitis
11 II, 5. 8. 3| in women). The 25-year cumulative incidence of moderate and
12 II, 5. 8. 4| Jugoslavia), the 30-year cumulative incidences of chronic bronchitis
13 II, 5. 8. 4| in women). The 25-year cumulative incidence of moderate and
14 II, 5. 8. 7| Lundback B (2005): Ten-year cumulative incidence of COPD and risk
15 II, 5. 8. 7| Lundback B (2006): Seven-year cumulative incidence of COPD in an
16 II, 5. 8. 7| Koskela H (2006): Thirty-year cumulative incidence of chronic bronchitis
17 II, 5. 11. 3| Europe~Point prevalence=1.7%~Cumulative incidence=2.1%)~Radulescu
18 II, 5. 11. 3| countries suggest an overall cumulative prevalence of between 5%
19 II, 5. 11. 3| be explained by increased cumulative sun exposure and increasing
20 II, 5. 11. 3| risk is strongly linked to cumulative lifetime sun exposure (Rosso
21 II, 9. 3. 1| both genders the lowest cumulative incidence and duration occurred
22 III, 10. 3. 1| experience a much higher cumulative exposure than previous generations.
23 III, 10. 4. 2| Spongiform Encephalopathy~CRA~Cumulative Risk Assessment~EFSA~European
24 III, 10. 4. 2| to take into account the cumulative and synergistic effects
25 III, 10. 4. 2| non-effective doses. Therefore, only cumulative risk assessment of compound
26 III, 10. 4. 2| of resources to carry out cumulative risk assessment. All have
27 III, 10. 4. 2| advantages and disadvantages. Cumulative risk assessments have been
28 III, 10. 4. 2| in Parma to discuss the Cumulative Risk Assessment (CRA) of
29 III, 10. 4. 2| probabilistic modelling and cumulative exposure assessment. Cooperation
30 III, 10. 4. 2| Scientific Colloquium on “Cumulative risk assessment of pesticides
